Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of “Moderate Buy” by Analysts

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $7.25.

PSTV has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Plus Therapeutics in a research note on Wednesday, November 26th. Zacks Research downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. D. Boral Capital restated a “buy” rating and issued a $5.00 target price on shares of Plus Therapeutics in a research note on Thursday, January 8th. Finally, Ascendiant Capital Markets cut their price target on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st.

Plus Therapeutics Trading Up 3.1%

PSTV stock opened at $0.29 on Thursday. The stock has a market cap of $39.98 million, a P/E ratio of -0.15 and a beta of 0.85. The stock’s fifty day simple moving average is $0.55 and its two-hundred day simple moving average is $0.54. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Plus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Plus Therapeutics in the 2nd quarter worth approximately $41,000. Susquehanna International Group LLP purchased a new stake in shares of Plus Therapeutics during the third quarter worth $46,000. Scientech Research LLC bought a new position in shares of Plus Therapeutics in the third quarter worth $100,000. Finally, Altium Capital Management LLC purchased a new stake in Plus Therapeutics during the 3rd quarter worth about $628,000. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.